AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31788323 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy Parent Carers (HPC) programme - peer-led, group-based intervention with online resources
Number of subjects: 0
Study 31788323 — intervention group
Group type: COMPARATOR
Intervention: Access to online resources only (control)
Number of subjects: 0
Study 31789119 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 31789601 — intervention group
Group type: EXPERIMENTAL
Intervention: MMA+ (Mindfulness Meditation app)
Number of subjects: 189
Study 31789601 — intervention group
Group type: COMPARATOR
Intervention: MMA- (Mindfulness Meditation without the app)
Number of subjects: 189
Study 31789686 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity and diet intake interventions
Number of subjects: 0
Study 31789834 — intervention group
Group type: EXPERIMENTAL
Intervention: Normoxia (brain tissue oxygen tension > 20 mm Hg)
Number of subjects: 14
Study 31789834 — intervention group
Group type: COMPARATOR
Intervention: Hypoxia (brain tissue oxygen tension < 20 mm Hg)
Number of subjects: 14
Study 31789834 — intervention group
Group type: COMPARATOR
Intervention: Comparison of normoxia vs hypoxia
Number of subjects: 14
Study 31789897 — intervention group
Group type: EXPERIMENTAL
Intervention: Transnasal flexible endoscopic laryngoscopy (TFEL)
Number of subjects: 169
Study 31789931 — intervention group
Group type: EXPERIMENTAL
Intervention: Allergen-specific immune signature-guided dietary elimination therapy
Number of subjects: 24
Study 31790126 — intervention group
Group type: EXPERIMENTAL
Intervention: Osteopathic manipulative treatment (OMT)
Number of subjects: 927
Study 31790472 — intervention group
Group type: EXPERIMENTAL
Intervention: Bayesian network algorithm applied to SLE gene network using transcriptomic data
Number of subjects: 1760
Study 31790472 — intervention group
Group type: EXPERIMENTAL
Intervention: Bayesian network algorithm
Number of subjects: 1760
Study 31790766 — intervention group
Group type: EXPERIMENTAL
Intervention: Sofosbuvir-based direct-acting antivirals (DAAs)
Number of subjects: 481
Study 31790766 — intervention group
Group type: COMPARATOR
Intervention: Sofosbuvir-free direct-acting antivirals (DAAs)
Number of subjects: 481
Study 31790959 — intervention group
Group type: EXPERIMENTAL
Intervention: EndoPredict® (EpClin) test
Number of subjects: 200
Study 31791337 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional small airway disease (fSAD) defined by CT and Parametric Response Mapping methodology
Number of subjects: 0
Study 31791337 — intervention group
Group type: EXPERIMENTAL
Intervention: CT-defined emphysema
Number of subjects: 0
Study 31791338 — intervention group
Group type: EXPERIMENTAL
Intervention: Neighbourhood Team Development (NTD) intervention, a 30-month standardized training and implementation plan.
Number of subjects: 6
Study 31791338 — intervention group
Group type: EXPERIMENTAL
Intervention: NTD intervention
Number of subjects: 6
Study 31792136 — intervention group
Group type: EXPERIMENTAL
Intervention: Interleukin-22 (IL22)
Number of subjects: 0
Study 31792136 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeting IL22
Number of subjects: 0
Study 31792136 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacological modulation of the ER stress response
Number of subjects: 0
Study 31792136 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibody blockade of IL12p40
Number of subjects: 0
Study 31792576 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-layer renorrhaphy
Number of subjects: 0
Study 31792576 — intervention group
Group type: COMPARATOR
Intervention: Traditional two-layer renorrhaphy
Number of subjects: 0
Study 31792696 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic migraine patients (CM)
Number of subjects: 52
Study 31792696 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls (HC)
Number of subjects: 52
Study 31792872 — intervention group
Group type: EXPERIMENTAL
Intervention: PTSD
Number of subjects: 5341
Study 31792872 — intervention group
Group type: EXPERIMENTAL
Intervention: Major depression
Number of subjects: 5341
Study 31792872 — intervention group
Group type: EXPERIMENTAL
Intervention: Anxiety disorders
Number of subjects: 5341
Study 31792889 — intervention group
Group type: EXPERIMENTAL
Intervention: Needle-free connectors (NFC)
Number of subjects: 111
Study 31792889 — intervention group
Group type: COMPARATOR
Intervention: Three-way hubs closed by caps (Control)
Number of subjects: 111
Study 31793850 — intervention group
Group type: EXPERIMENTAL
Intervention: FDG PET/MRI with dedicated liver and rectal MRI
Number of subjects: 0
Study 31793850 — intervention group
Group type: COMPARATOR
Intervention: Chest and abdominopelvic CT
Number of subjects: 0
Study 31793891 — intervention group
Group type: EXPERIMENTAL
Intervention: PAGETEX medical device with Metvixia, administered in two PDT sessions at 15-day intervals (Metvixia incubation for 30 minutes and 635 nm red light illumination for 2 hours and 30 minutes, total fluence of 12 J/cm²)
Number of subjects: 24
Study 31793891 — intervention group
Group type: EXPERIMENTAL
Intervention: PAGETEX medical device with Metvixia, administered in two PDT sessions at 15-day intervals
Number of subjects: 24
Study 31793897 — intervention group
Group type: EXPERIMENTAL
Intervention: selfBACK app in addition to usual care
Number of subjects: 350
Study 31793897 — intervention group
Group type: COMPARATOR
Intervention: usual care only
Number of subjects: 350
Study 31794031 — intervention group
Group type: EXPERIMENTAL
Intervention: Support for HIV infection and substance use treatment
Number of subjects: 445
Study 31794031 — intervention group
Group type: EXPERIMENTAL
Intervention: Phylogenetic analysis of pol sequences
Number of subjects: 445
Study 31794031 — intervention group
Group type: EXPERIMENTAL
Intervention: Next-generation sequencing (NGS, env region)
Number of subjects: 445
Study 31794605 — intervention group
Group type: EXPERIMENTAL
Intervention: Gender-affirming treatment in transgender men (TM)
Number of subjects: 23
Study 31794605 — intervention group
Group type: EXPERIMENTAL
Intervention: Gender-affirming treatment in transgender women (TW)
Number of subjects: 23
Study 31794700 — intervention group
Group type: EXPERIMENTAL
Intervention: Graded transthoracic contrast echocardiography (TTCE)
Number of subjects: 32
Study 31794742 — intervention group
Group type: EXPERIMENTAL
Intervention: VCD (MANTA; Teleflex/Essential Medical, Malvern, PA)
Number of subjects: 268
Study 31794742 — intervention group
Group type: COMPARATOR
Intervention: Surgical cutdown
Number of subjects: 268
Study 31795071 — intervention group
Group type: EXPERIMENTAL
Intervention: Convection-Enhanced Delivery of a TGFβ
Number of subjects: 0
Study 31795926 — intervention group
Group type: EXPERIMENTAL
Intervention: Male circumcision
Number of subjects: 0
Study 31795926 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-circumcised men)
Number of subjects: 0
Study 31795981 — intervention group
Group type: EXPERIMENTAL
Intervention: Mass Testing, Treatment and Tracking (MTTT)
Number of subjects: 5000
Study 31796469 — intervention group
Group type: EXPERIMENTAL
Intervention: MK-3475 (200 mg every 21 days) in combination with BCG
Number of subjects: 20
Study 31796469 — intervention group
Group type: COMPARATOR
Intervention: BCG
Number of subjects: 20
Study 31796491 — intervention group
Group type: EXPERIMENTAL
Intervention: Regional cerebral oxygen saturation (rSO2) monitoring during surgery
Number of subjects: 95
Study 31796939 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative chemical vestibular ablation with 0.5 - 1.0 mL of 40 mg/mL nonbuffered gentamicin administered in three intratympanic instillations.
Number of subjects: 32
Study 31796939 — intervention group
Group type: COMPARATOR
Intervention: Control group (no preoperative gentamicin treatment).
Number of subjects: 32
Study 31796953 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fructose diet (150 g daily) for 8 weeks
Number of subjects: 10
Study 31796953 — intervention group
Group type: COMPARATOR
Intervention: NAFLD patients (positive control)
Number of subjects: 10
Study 31797105 — intervention group
Group type: EXPERIMENTAL
Intervention: IgM-enriched immunoglobulins (Pentaglobin) 250 mg/kg (5 mL/kg) per day for 72 hours
Number of subjects: 19
Study 31797105 — intervention group
Group type: COMPARATOR
Intervention: Placebo (NaCl 0.9%)
Number of subjects: 19
Study 31798447 — intervention group
Group type: EXPERIMENTAL
Intervention: Ayahuasca (one dose)
Number of subjects: 0
Study 31798447 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31798516 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 31798754 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein-enriched milk (2 × 20 g protein/day)
Number of subjects: 0
Study 31798754 — intervention group
Group type: COMPARATOR
Intervention: Carbohydrates
Number of subjects: 0
Study 31798950 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity interval training (HIIT)
Number of subjects: 20
Study 31798950 — intervention group
Group type: COMPARATOR
Intervention: Moderate-intensity continuous training (MICT)
Number of subjects: 20
Study 31798950 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 20
Study 31798984 — intervention group
Group type: EXPERIMENTAL
Intervention: Samvedana Plus
Number of subjects: 620
Study 31798984 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 620
Study 31799207 — intervention group
Group type: EXPERIMENTAL
Intervention: Sorafenib
Number of subjects: 0
Study 31799207 — intervention group
Group type: COMPARATOR
Intervention: Combination of sorafenib and hepatic arterial infusion chemotherapy
Number of subjects: 0
Study 31799472 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 31799498 — intervention group
Group type: EXPERIMENTAL
Intervention: TNF inhibitors (infliximab, etanercept, adalimumab, MTX)
Number of subjects: 4315
Study 31799498 — intervention group
Group type: EXPERIMENTAL
Intervention: Ustekinumab
Number of subjects: 4315
Study 31799498 — intervention group
Group type: COMPARATOR
Intervention: Non-biologic/methotrexate (MTX)
Number of subjects: 4315
Study 31799498 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-biologic/non-MTX
Number of subjects: 4315
Study 31800543 — intervention group
Group type: EXPERIMENTAL
Intervention: Fecobionics
Number of subjects: 20
Study 31800543 — intervention group
Group type: COMPARATOR
Intervention: Balloon Expulsion Test (BET)
Number of subjects: 20
Study 31801624 — intervention group
Group type: EXPERIMENTAL
Intervention: Utomilumab 1.2-5 mg/kg or 100 mg flat dose every 4 weeks plus mogamulizumab 1 mg/kg (weekly in Cycle 1 followed by biweekly in Cycles ≥2)
Number of subjects: 24
Study 31801624 — intervention group
Group type: EXPERIMENTAL
Intervention: Utomilumab/mogamulizumab combination
Number of subjects: 24
Study 31801732 — intervention group
Group type: EXPERIMENTAL
Intervention: Tremelimumab monotherapy (750 mg via intravenous infusion every 4 weeks for seven cycles, then every 12 weeks for two additional cycles)
Number of subjects: 32
Study 31802302 — intervention group
Group type: EXPERIMENTAL
Intervention: < 10 Ncm insertion torque
Number of subjects: 12
Study 31802302 — intervention group
Group type: EXPERIMENTAL
Intervention: ~ 30 Ncm insertion torque
Number of subjects: 12
Study 31802369 — intervention group
Group type: EXPERIMENTAL
Intervention: Vagal modulation of arousal (indexed by respiratory sinus arrhythmia - RSA)
Number of subjects: 105
Study 31802410 — intervention group
Group type: EXPERIMENTAL
Intervention: FOLFIRI + Sunitinib (S)
Number of subjects: 23
Study 31802485 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastric suctioning
Number of subjects: 61
Study 31802485 — intervention group
Group type: COMPARATOR
Intervention: Erythromycin infusion
Number of subjects: 61
Study 31802967 — intervention group
Group type: EXPERIMENTAL
Intervention: Ensemble method combining k-nearest neighbor and supervised fuzzy c-means
Number of subjects: 3962
Study 31802967 — intervention group
Group type: EXPERIMENTAL
Intervention: k-nearest neighbor
Number of subjects: 3962
Study 31802967 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised fuzzy c-means
Number of subjects: 3962
Study 31803056 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean Diet Enriched in High Quality Extra Virgin Olive Oil
Number of subjects: 0
Study 31803089 — intervention group
Group type: EXPERIMENTAL
Intervention: Bergen 4-day treatment (B4DT)
Number of subjects: 48
Study 31803089 — intervention group
Group type: COMPARATOR
Intervention: Self-help (SH)
Number of subjects: 48
Study 31803089 — intervention group
Group type: COMPARATOR
Intervention: Waiting list (WL)
Number of subjects: 48
Study 31803481 — intervention group
Group type: EXPERIMENTAL
Intervention: DSPN+
Number of subjects: 304
Study 31803481 — intervention group
Group type: COMPARATOR
Intervention: DSPN-
Number of subjects: 304
Study 31803481 — intervention group
Group type: COMPARATOR
Intervention: NGT
Number of subjects: 304
Study 31803494 — intervention group
Group type: COMPARATOR
Intervention: Allocation to 60 min school PA/week
Number of subjects: 199
Study 31803494 — intervention group
Group type: EXPERIMENTAL
Intervention: Female sex
Number of subjects: 199
Study 31803494 — intervention group
Group type: EXPERIMENTAL
Intervention: Each 10 cm shorter body height
Number of subjects: 199
Study 31803494 — intervention group
Group type: EXPERIMENTAL
Intervention: Each unit higher body mass index (BMI)
Number of subjects: 199
Study 31803487 — intervention group
Group type: EXPERIMENTAL
Intervention: Prehospital 12-lead ECG (PHECG)
Number of subjects: 0
Study 31803509 — intervention group
Group type: EXPERIMENTAL
Intervention: Appointment scheduling intervention
Number of subjects: 8385
Study 31803509 — intervention group
Group type: COMPARATOR
Intervention: Control group (first come, first served)
Number of subjects: 8385
Study 31803694 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc supplementation
Number of subjects: 0
Study 31803694 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 31803710 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 31803847 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled Human Malaria Infection (CHMI)
Number of subjects: 0
Study 31804102 — intervention group
Group type: EXPERIMENTAL
Intervention: IRT-calibrated CAPS
Number of subjects: 0
Study 31804102 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-calibrated CAPS
Number of subjects: 0
Study 31804102 — intervention group
Group type: COMPARATOR
Intervention: Uncalibrated MPSS scores
Number of subjects: 0
Study 31804102 — intervention group
Group type: COMPARATOR
Intervention: Uncalibrated CAPS scores
Number of subjects: 0
Study 31804281 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based legacy intervention
Number of subjects: 81
Study 31804299 — intervention group
Group type: EXPERIMENTAL
Intervention: Sepsis patients in ICU
Number of subjects: 2322
Study 31804299 — intervention group
Group type: EXPERIMENTAL
Intervention: Sepsis patients with severe sepsis
Number of subjects: 2322
Study 31804299 — intervention group
Group type: EXPERIMENTAL
Intervention: Sepsis patients with septic shock
Number of subjects: 2322
Study 31804299 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with pneumonia as infection site
Number of subjects: 2322
Study 31804299 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with bloodstream infection as infection site
Number of subjects: 2322
Study 31804299 — intervention group
Group type: EXPERIMENTAL
Intervention: Older age
Number of subjects: 2322
Study 31804299 — intervention group
Group type: EXPERIMENTAL
Intervention: Low body weight
Number of subjects: 2322
Study 31804299 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher Sequential Organ Failure Assessment score
Number of subjects: 2322
Study 31804299 — intervention group
Group type: EXPERIMENTAL
Intervention: Number of systemic inflammatory response syndrome criteria
Number of subjects: 2322
Study 31804299 — intervention group
Group type: EXPERIMENTAL
Intervention: Comorbid conditions (heart failure, hematologic cancer, immunosuppression)
Number of subjects: 2322
Study 31804299 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher level of lactate
Number of subjects: 2322
Study 31804669 — intervention group
Group type: EXPERIMENTAL
Intervention: Elvitegravir-Cobicistat-Emtricitabine-Tenofovir Alafenamide single-tablet regimen
Number of subjects: 0
Study 31804967 — intervention group
Group type: EXPERIMENTAL
Intervention: Total thyroidectomy for benign thyroid disease
Number of subjects: 800
Study 31804967 — intervention group
Group type: EXPERIMENTAL
Intervention: Total thyroidectomy for malignant thyroid disease
Number of subjects: 800
Study 31804967 — intervention group
Group type: EXPERIMENTAL
Intervention: Total thyroidectomy for Graves' disease
Number of subjects: 800
Study 31804967 — intervention group
Group type: COMPARATOR
Intervention: Postoperative complications
Number of subjects: 800
Study 31805015 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss (10%) in obese-NAFLD group
Number of subjects: 67
Study 31805015 — intervention group
Group type: EXPERIMENTAL
Intervention: Obese-NAFLD group
Number of subjects: 67
Study 31805015 — intervention group
Group type: EXPERIMENTAL
Intervention: Obese group
Number of subjects: 67
Study 31805015 — intervention group
Group type: EXPERIMENTAL
Intervention: Lean group
Number of subjects: 67
Study 31805015 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall correlation
Number of subjects: 67
Study 31805182 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabigatran etexilate
Number of subjects: 203
Study 31805424 — intervention group
Group type: EXPERIMENTAL
Intervention: N-terminal pro-B-type natriuretic peptide (NT-proBNP)
Number of subjects: 441
Study 31805424 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel biomarkers (soluble ST2, growth differentiation factor-15, Galectin-3)
Number of subjects: 441
Study 31805921 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfapump system (AP)
Number of subjects: 17
Study 31805926 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical complications
Number of subjects: 1055
Study 31805926 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical complications
Number of subjects: 1055
Study 31806098 — intervention group
Group type: EXPERIMENTAL
Intervention: Total sugars
Number of subjects: 624128
Study 31806098 — intervention group
Group type: EXPERIMENTAL
Intervention: Fructose
Number of subjects: 624128
Study 31806098 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucrose
Number of subjects: 624128
Study 31806098 — intervention group
Group type: EXPERIMENTAL
Intervention: Added sugars
Number of subjects: 624128
Study 31806360 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate to severe depressive symptoms
Number of subjects: 186
Study 31806360 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate depressive symptoms
Number of subjects: 186
Study 31806360 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall depressive symptoms
Number of subjects: 186
Study 31806397 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline serum betaine <77.7 μmol/L
Number of subjects: 622
Study 31806397 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline serum betaine ≥77.7 μmol/L
Number of subjects: 622
Study 31806397 — intervention group
Group type: COMPARATOR
Intervention: Serum betaine
Number of subjects: 622
Study 31806391 — intervention group
Group type: EXPERIMENTAL
Intervention: CTA-derived RESOLVE score
Number of subjects: 363
Study 31806391 — intervention group
Group type: COMPARATOR
Intervention: Angiographic V-RESOLVE score
Number of subjects: 363
Study 31806391 — intervention group
Group type: COMPARATOR
Intervention: Non-high-risk group (CTA-derived RESOLVE)
Number of subjects: 363
Study 31806391 — intervention group
Group type: COMPARATOR
Intervention: High-risk group (CTA-derived RESOLVE)
Number of subjects: 363
Study 31806403 — intervention group
Group type: EXPERIMENTAL
Intervention: Active tDCS
Number of subjects: 45
Study 31806403 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 45
Study 31806470 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive lifestyle intervention (diet and physical activity) for 8 weeks
Number of subjects: 41
Study 31806613 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol optimal dosing pathway
Number of subjects: 1000
Study 31806722 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute diesel exhaust exposure
Number of subjects: 0
Study 31806722 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 31806930 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranibizumab injections
Number of subjects: 744
Study 31807036 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil fumarate (TDF) treatment starting from the second trimester (24-27 weeks)
Number of subjects: 129
Study 31807036 — intervention group
Group type: COMPARATOR
Intervention: Tenofovir disoproxil fumarate (TDF) treatment starting from the third trimester (28-30 weeks)
Number of subjects: 129
Study 31807102 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvoxamine for 8 weeks
Number of subjects: 31
Study 31807350 — intervention group
Group type: EXPERIMENTAL
Intervention: Diamine oxidase (DAO) supplementation for 4 weeks before meals
Number of subjects: 28
Study 31807350 — intervention group
Group type: COMPARATOR
Intervention: Follow-up period without DAO supplementation
Number of subjects: 28
Study 31807567 — intervention group
Group type: EXPERIMENTAL
Intervention: Terlipressin
Number of subjects: 60
Study 31807567 — intervention group
Group type: COMPARATOR
Intervention: Octreotide
Number of subjects: 60
Study 31808620 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 20
Study 31809241 — intervention group
Group type: EXPERIMENTAL
Intervention: Osimertinib 160 mg once daily
Number of subjects: 41
Study 31809243 — intervention group
Group type: EXPERIMENTAL
Intervention: Trastuzumab and Pertuzumab with neoadjuvant chemoradiotherapy (nCRT)
Number of subjects: 40
Study 31809243 — intervention group
Group type: COMPARATOR
Intervention: HER2 blockade (trastuzumab and pertuzumab)
Number of subjects: 40
Study 31809506 — intervention group
Group type: EXPERIMENTAL
Intervention: Elective cesarean section (CS)
Number of subjects: 97291
Study 31809506 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonelective cesarean section (CS)
Number of subjects: 97291
Study 31809506 — intervention group
Group type: COMPARATOR
Intervention: Vaginal delivery
Number of subjects: 97291
Study 31809506 — intervention group
Group type: EXPERIMENTAL
Intervention: Any form of cesarean section (elective or nonelective)
Number of subjects: 97291
Study 31809725 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant E1E2 complex vaccine
Number of subjects: 551
Study 31810059 — intervention group
Group type: EXPERIMENTAL
Intervention: Having network members who exercised
Number of subjects: 689